Steve Brozak
Stock Analyst at WBB Securities
(0.08)
# 4,112
Out of 4,818 analysts
7
Total ratings
11.11%
Success rate
-22.65%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Steve Brozak
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRKR Marker Therapeutics | Reiterates: Strong Buy | $13 | $1.19 | +950.42% | 1 | Apr 1, 2025 | |
| CDTX Cidara Therapeutics | Upgrades: Strong Buy | n/a | $21.98 | - | 1 | Sep 22, 2021 | |
| OMER Omeros | Maintains: Strong Buy | $75 → $100 | $7.15 | +1,298.60% | 2 | Jun 18, 2021 | |
| RDHL RedHill Biopharma | Downgrades: Buy | $17,000 → $16,000 | $2.31 | +692,540.69% | 3 | May 28, 2021 |
Marker Therapeutics
Apr 1, 2025
Reiterates: Strong Buy
Price Target: $13
Current: $1.19
Upside: +950.42%
Cidara Therapeutics
Sep 22, 2021
Upgrades: Strong Buy
Price Target: n/a
Current: $21.98
Upside: -
Omeros
Jun 18, 2021
Maintains: Strong Buy
Price Target: $75 → $100
Current: $7.15
Upside: +1,298.60%
RedHill Biopharma
May 28, 2021
Downgrades: Buy
Price Target: $17,000 → $16,000
Current: $2.31
Upside: +692,540.69%